Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations

Journal of Medical Economics
Eytan M SteinGeorge J Joseph

Abstract

To describe the setting, duration, and costs of induction and consolidation chemotherapy for adults with newly-diagnosed acute myeloid leukemia (AML), who are candidates for standard induction chemotherapy, in the US. Adults newly-diagnosed with AML who received standard induction chemotherapy in an inpatient setting were identified from the Truven Health Analytics MarketScan (2006-2015) and SEER-Medicare (2007-2011) databases. Patients were observed from induction therapy start to the first of hematopoietic stem cell transplant, 180 days after induction discharge, health plan enrollment/data availability end, or death. Induction and consolidation chemotherapy were identified using Diagnosis-Related Group codes (chemotherapy with acute leukemia) or procedure codes for AML chemotherapy administration. AML treatment episode setting (inpatient or outpatient), duration, and costs (2015 USD, payers' perspective) were described for commercially insured patients and Medicare beneficiaries. In total, 459 commercially insured patients and 563 Medicare beneficiaries (mean age = 54 and 66 years; 53% and 54% male; respectively) were identified. For induction therapy, mean costs were $145,189 for commercially insured patients and $85,734 fo...Continue Reading

References

Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Jul 19, 2002·Archives of Internal Medicine·Joseph MenzinRajiv Mallick
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Dec 4, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Ramalingam Rathnasabapathy, Jeffrey E Lancet
Apr 3, 2004·Cancer Treatment Reviews·Alberto RedaelliChris L Pashos
Oct 5, 2006·Cancer·Barbara Deschler, Michael Lübbert
Nov 14, 2007·Journal of Cancer Research and Therapeutics·N UdayakumarR Muthuselvan
May 20, 2009·Cancer·Shabbir M H AlibhaiJoseph Brandwein
Jan 13, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Benjamin M CraigChristopher R Cogle
Jun 27, 2013·Nature Reviews. Clinical Oncology·Christopher S Hourigan, Judith E Karp
Nov 17, 2015·Expert Review of Hematology·Amer M ZeidanB Douglas Smith
Dec 15, 2015·Blood·Eytan M Stein, Martin S Tallman
Jul 14, 2016·Leukemia Research Reports·Antonio M Almeida, Fernando Ramos
Nov 29, 2016·JAMA : the Journal of the American Medical Association·Areej El-JawahriJennifer S Temel
Feb 2, 2017·Current Treatment Options in Oncology·Xavier Thomas, Caroline Le Jeune
Mar 7, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jaime M PreusslerDavid J Vanness
Sep 23, 2018·Health and Quality of Life Outcomes·Eytan M SteinGeorge J Joseph

❮ Previous
Next ❯

Citations

Dec 27, 2018·Current Opinion in Hematology·Anna B HalpernElihu H Estey
Aug 21, 2018·Journal of Medical Economics·May HagiwaraThomas E Delea
Jun 5, 2019·Expert Review of Hematology·Jan Philipp BewersdorfAmer M Zeidan
Oct 8, 2020·Current Oncology Reports·Luis Antonio Meillon-Garcia, Roberta Demichelis-Gómez
Sep 16, 2021·Blood Advances·Jan Philipp BewersdorfAmer M Zeidan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.